Plain-English translation of NCT06728462 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a medication called amorphous calcium carbonate (sold as DensityTM) to see if it can help strengthen bones in postmenopausal women who have low bone density. Some participants will take the calcium supplement alone, while others will take it along with injections of denosumab (ProliaTM), another bone-strengthening medicine. The study will track how well the treatment works by measuring bone density and bone health markers over 2 years.
Postmenopausal women often develop weak bones that break easily. This trial is trying to find out whether this medication can effectively prevent bone loss and improve bone strength in women with significant bone density problems.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic 7 times over 2 years — at the start, then at 1, 6, 12, 18, and 24 months. At most visits, you'll have your bone density measured and blood drawn. Every day, you'll take 5 tablets of the calcium supplement with meals. Depending on your vitamin D levels, you'll also take a daily vitamin D supplement. If you're in the injection group, you'll receive a bone-strengthening injection every 6 months at the clinic. The whole study lasts 24 months.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Taiwan
Sponsor
Universal Integrated Corp.
Collaborators
Chang Gung Memorial Hospital
Enrollment target
~205 participants
Started
March 2025
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
60 Years – 90 Years
Sex
Female only
Last updated on clinicaltrials.gov in March 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.